Sight Sciences Announces Addition of New Director Catherine Mazzacco
09 Junho 2023 - 5:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the
“Company”), an eyecare technology company focused on creating
innovative solutions intended to transform care and improve
patients’ lives, today announces that Catherine Mazzacco was
elected to the Company’s board of directors at its Annual Meeting
of Stockholders held on June 8, 2023. Ms. Mazzacco will serve as a
Class II director with a term expiring at the 2026 Annual Meeting
of Stockholders.
“We are very excited to have Catherine on our
board of directors. We have added an industry veteran with a track
record of success in commercial and operational leadership at large
healthcare businesses with global scale. Catherine’s experience at
Abbott, as General Manager of its Immunology division that launched
Humira, one of the most successful healthcare products on record,
and leading the global commercial operations for Abbott’s AMO
ophthalmic division, is particularly relevant to the continued
growth and global expansion of Sight Sciences. Catherine’s
strategic insight will further elevate our company as we scale our
business,” said Paul Badawi, co-founder and Chief Executive Officer
of Sight Sciences.
Ms. Mazzacco added, “I am thrilled to join the
board of Sight Sciences at this exciting time as the glaucoma and
dry eye categories are undergoing significant transformation and
the company advances its compelling product pipeline. Sight
Sciences is very well positioned to enhance the lives of patients
around the world by elevating the standards of care in eyecare
while delivering significant value to the ophthalmic community and
stakeholders. I look forward to collaborating with this top-tier
team and board to help the company achieve its growth and
profitability objectives.”
Ms. Mazzacco was formerly Chief Executive
Officer and President of LEO Pharma, a privately owned global
pharmaceutical company, and a member of its board of directors from
August 2019 to November 2021. Prior to this role, Ms. Mazzacco was
Senior Vice President, Global Commercial Operations, of the Life
Sciences Division at GE HealthCare, a leading global medical
technology, pharmaceutical, diagnostics and life sciences company,
from February 2018 to May 2019. Before joining GE HealthCare, Ms.
Mazzacco spent over 25 years at Abbott Laboratories, a major
multinational publicly traded healthcare company where she held
several global senior operational and strategic leadership roles,
including Vice President, Global Commercial Operations, of the
Abbott Vision Division from 2011 to 2017. Ms. Mazzacco has served
as a member of the board of directors of Krystal Biotech, Inc.
since March 2023. Ms. Mazzacco is also a Member of the
Supervisory Board of Servier, a privately owned global
pharmaceutical company. Ms. Mazzacco holds a Bachelor of Science in
Engineering, Option Biotechnology from the University of Compiègne
in France.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative solutions intended to transform care and
improve patients’ lives. Using minimally invasive or non-invasive
approaches to target the underlying causes of the world’s most
prevalent eye diseases, Sight Sciences seeks to create more
effective treatment paradigms that enhance patient care and
supplant conventional outdated approaches. The Company’s
OMNI® Surgical System is a minimally invasive glaucoma surgery
(MIGS) device indicated to reduce intraocular pressure in adult
patients with primary open-angle glaucoma (POAG), the world’s
leading cause of irreversible blindness. The SION™ Surgical
Instrument is a bladeless, manually operated device used in
ophthalmic surgical procedures to excise trabecular meshwork. The
Company’s TearCare® System is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (MGD), enabling office-based clearance of gland
obstructions by physicians to address the leading cause of dry eye
disease.
For more information,
visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight
Sciences.SION™ is a trademark of Sight Sciences.© 2023 Sight
Sciences. All rights reserved.
Forward-Looking StatementsThis
press release, together with other statements and information
publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which statements are
subject to considerable risks and uncertainties. The Company
intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with these safe harbor
provisions. Any statements made in this press release that are not
statements of historical fact, including statements about our
beliefs and expectations, are forward-looking statements and should
be evaluated as such. Forward-looking statements include all
statements other than statements of historical fact, including
statements concerning the anticipated benefits arising out of the
announced election of Catherine Mazzacco to the Company’s Board of
Directors and the Company’s ability to enhance the lives of
patients around the world by elevating the standards of care in
eyecare while delivering significant value to the ophthalmic
community and stakeholders, and should be evaluated as such. These
statements often include words such as “anticipate,” “expect,”
“suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,”
“projects,” “should,” “could,” “would,” “may,” “will,” “forecast”
and other similar expressions. We base these forward-looking
statements on our current expectations, plans and assumptions that
we have made in light of our experience in the industry, as well as
our perceptions of historical trends, current conditions, expected
future developments and other factors we believe are appropriate
under the circumstances at such time. Although management believes
these forward-looking statements are based upon reasonable
assumptions at the time they are made, management cannot guarantee
their accuracy or completeness. Forward-looking statements are
subject to and involve risks, uncertainties and assumptions that
may cause the Company’s actual results, performance or achievements
to be materially different from any future results, performance, or
achievements predicted, assumed or implied by such forward-looking
statements. Some of the risks and uncertainties that may cause
actual results to materially differ from those expressed or implied
by these forward-looking statements are discussed under the caption
“Risk Factors” in the Company’s filings with the SEC, as may be
updated from time to time in subsequent filings. These cautionary
statements should not be construed by you to be exhaustive and are
made only as of the date of this press release. Sight Sciences
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by applicable law.
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024